Table 2.
Radiological, biomechanical and micro-CT analysis 2, 5 and 10 weeks after fracture of perindopril-treated and untreated animals
|
2 weeks |
5 weeks |
10 weeks |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Perindopril | Control | P | Perindopril | Control | P | Perindopril | Control | P | |
| Radiology | |||||||||
| Cl.Dm/F.Dm (%) | 111.3 ± 4.0 | 104.2 ± 2.1 | 0.14 | 139.7 ± 4a | 134.1 ± 9.6 | 0.57 | 124.0 ± 5.1 | 137.3 ± 4.5 | 0.06 |
| Goldberg score | 0.5 ± 0.1 | 0.6 ± 0.2 | 0.14 | 1.3 ± 0.2 | 1.2 ± 0.2 | 0.80 | 1.6 ± 0.1 | 1.9 ± 0.1 | 0.08 |
| Biomechanics | |||||||||
| Max. torque (%) | 0.3 ± 0.0 | 0.1 ± 0.03 | <0.001 | 97.2 ± 18.5 | 65.0 ± 12.6 | 0.18 | 80.3 ± 8.2 | 85.2 ± 6.6 | 0.65 |
| Angle (%) | 98.8 ± 16.5 | 81.3 ± 18.9 | 0.50 | 70.4 ± 6.5 | 94.9 ± 17.1 | 0.21 | 89.5 ± 18.8 | 82.4 ± 4.8 | 0.72 |
| Stiffness (%) | 0.5 ± 0.2 | 0.2 ± 0.1 | 0.12 | 148.1 ± 35.1 | 74.5 ± 13.0 | 0.07 | 113.6 ± 21.8 | 104.4 ± 6.9 | 0.70 |
| Micro-CT analysis | |||||||||
| Bone volume (mm3) | 3.9 ± 0.2 | 4.7 ± 0.3 | 0.06 | ||||||
| BMD (mgHA·mm−3) | 1058.0 ± 7.6 | 1051.0 ± 10.5 | 0.60 | ||||||
Data are mean ± SEM.
a
P < 0.05 versus perindopril-treated animals after 10 weeks.
BMD, bone mineral density; Cl.Dm/F.Dm, maximum callus diameter/femur diameter.